تقدم ساركومة كابوزي المرتبطة بالإيدز رغم العلاج المضاد للفيروسات القهقرية

References

DOI: 10.1111/ddg.14788

• For systemic therapy of KS, chemotherapy with pegylated liposomal doxorubicin should be the first choice.
• Pegylated liposomal doxorubicine at a dose of 20 mg/m2 body surface area i.v. every 2–3 weeks can achieve partial remissions in up to 60–80 % of treated patients.
• An alternative for doxorubicine is liposomal daunorubicine, which is probably somewhat less effective.
• Liposomal daunorubicine (DaunoXome®) is given at a dose of 40 mg/m2 KO i.v. every two weeks.
• If KS recurs despite efficient ART or if existing KS does not show regression, low doses of IFN-α are usually sufficient to treat KS.
• Initially, in combination with ART, 3–9 million IU IFN-α are applied daily, later 3–5 x/week, s.c.
• Interferon should therefore only be considered in KS patients with more than 200 CD4 cells/μl.
• Treatment response is assessed by clinical examination of the lesions.
• In addition to subjective parameters, the size, thickness and coloration of the tumors as well as the presence of edema serve as criteria.
• In most cases, a profound partial remission is achieved after about 3–6 infusions, whereas some patients require more infusions to achieve a response.